Genmab AS Net Worth
Genmab AS Net Worth Breakdown | GMAB |
Genmab AS Net Worth Analysis
Genmab AS's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Genmab AS's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Genmab AS's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Genmab AS's net worth analysis. One common approach is to calculate Genmab AS's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Genmab AS's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Genmab AS's net worth. This approach calculates the present value of Genmab AS's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Genmab AS's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Genmab AS's net worth. This involves comparing Genmab AS's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Genmab AS's net worth relative to its peers.
Enterprise Value |
|
To determine if Genmab AS is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Genmab AS's net worth research are outlined below:
| Genmab AS is unlikely to experience financial distress in the next 2 years | |
| Genmab AS has a strong financial position based on the latest SEC filings | |
| Latest headline from thelincolnianonline.com: Genmab AS Sees Large Volume Increase Whats Next |
Genmab AS uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Genmab AS. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Genmab AS's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Genmab AS Target Price Consensus
Genmab target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Genmab AS's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 9 | Buy |
Most Genmab analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Genmab stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Genmab AS, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationGenmab AS Target Price Projection
Genmab AS's current and average target prices are 20.51 and 36.56, respectively. The current price of Genmab AS is the price at which Genmab AS is currently trading. On the other hand, Genmab AS's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Genmab AS Target Price
Know Genmab AS's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Genmab AS is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Genmab AS backward and forwards among themselves. Genmab AS's institutional investor refers to the entity that pools money to purchase Genmab AS's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | First Trust Advisors L.p. | 2024-12-31 | 1.6 M | Brandywine Global Investment Mgmt Llc | 2024-12-31 | 1.6 M | Ubs Group Ag | 2024-12-31 | 1.4 M | Marshall Wace Asset Management Ltd | 2024-12-31 | 1.1 M | Voloridge Investment Management, Llc | 2024-12-31 | 1.1 M | Millennium Management Llc | 2024-12-31 | 927.8 K | Goldman Sachs Group Inc | 2024-12-31 | 773.1 K | Envestnet Asset Management Inc | 2024-12-31 | 723.8 K | Northern Trust Corp | 2024-12-31 | 599.4 K | Alliancebernstein L.p. | 2024-12-31 | 14.9 M | Blackrock Inc | 2024-12-31 | 4.2 M |
Follow Genmab AS's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 13.07 B.Market Cap |
|
Project Genmab AS's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.25 | 0.27 | |
| Return On Capital Employed | 0.17 | 0.17 | |
| Return On Assets | 0.17 | 0.18 | |
| Return On Equity | 0.21 | 0.22 |
When accessing Genmab AS's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Genmab AS's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Genmab AS's profitability and make more informed investment decisions.
Please note, the presentation of Genmab AS's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Genmab AS's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Genmab AS's management manipulating its earnings.
Evaluate Genmab AS's management efficiency
Genmab AS has return on total asset (ROA) of 0.1091 % which means that it generated a profit of $0.1091 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2297 %, meaning that it created $0.2297 on every $100 dollars invested by stockholders. Genmab AS's management efficiency ratios could be used to measure how well Genmab AS manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.27. The current year's Return On Capital Employed is expected to grow to 0.17. At present, Genmab AS's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 18.9 B, whereas Other Current Assets are forecasted to decline to about 110.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 567.76 | 596.15 | |
| Tangible Book Value Per Share | 337.58 | 354.46 | |
| Enterprise Value Over EBITDA | 11.86 | 13.25 | |
| Price Book Value Ratio | 2.63 | 2.50 | |
| Enterprise Value Multiple | 11.86 | 13.25 | |
| Price Fair Value | 2.63 | 2.50 | |
| Enterprise Value | 80.9 B | 85 B |
Evaluating the management effectiveness of Genmab AS allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Genmab Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 3.242 | Revenue | Quarterly Revenue Growth 0.353 | Revenue Per Share | Return On Equity |
Genmab AS Corporate Filings
6K | 12th of March 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
Genmab AS Earnings Estimation Breakdown
The calculation of Genmab AS's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Genmab AS is estimated to be 0.2473 with the future projection ranging from a low of 0.2274 to a high of 0.2671. Please be aware that this consensus of annual earnings estimates for Genmab AS is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.23 Lowest | Expected EPS | 0.27 Highest |
Genmab AS Earnings Projection Consensus
Suppose the current estimates of Genmab AS's value are higher than the current market price of the Genmab AS stock. In this case, investors may conclude that Genmab AS is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Genmab AS's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 9 | 61.12% | 0.8351 | 0.2473 | 1.77 |
Genmab AS Earnings per Share Projection vs Actual
Actual Earning per Share of Genmab AS refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Genmab AS predict the company's earnings will be in the future. The higher the earnings per share of Genmab AS, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Genmab AS Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Genmab AS, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Genmab AS should always be considered in relation to other companies to make a more educated investment decision.Genmab Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Genmab AS's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-12 | 2024-12-31 | 0.3585 | 0.8351 | 0.4766 | 132 | ||
2024-11-06 | 2024-09-30 | 0.35 | 0.29 | -0.06 | 17 | ||
2024-08-08 | 2024-06-30 | 0.33 | 0.31 | -0.02 | 6 | ||
2024-05-02 | 2024-03-31 | 0.14 | 0.29 | 0.15 | 107 | ||
2024-02-14 | 2023-12-31 | 3.99 | 0.14 | -3.85 | 96 | ||
2023-11-07 | 2023-09-30 | 3.14 | 0.47 | -2.67 | 85 | ||
2023-08-03 | 2023-06-30 | 2.18 | 0.3 | -1.88 | 86 | ||
2023-05-10 | 2023-03-31 | 0.65 | 0.05 | -0.6 | 92 | ||
2023-02-22 | 2022-12-31 | 3.15 | 0.12 | -3.03 | 96 | ||
2022-11-09 | 2022-09-30 | 1.65 | 0.53 | -1.12 | 67 | ||
2022-08-10 | 2022-06-30 | 1.55 | 0.41 | -1.14 | 73 | ||
2022-05-11 | 2022-03-31 | 0.91 | 0.11 | -0.8 | 87 | ||
2022-02-16 | 2021-12-31 | 5.3 | 0.17 | -5.13 | 96 | ||
2021-11-10 | 2021-09-30 | 0.1315 | 0.21 | 0.0785 | 59 | ||
2021-08-11 | 2021-06-30 | 0.0723 | 0.08 | 0.0077 | 10 | ||
2021-05-21 | 2021-03-31 | 0.23 | 0.27 | 0.04 | 17 | ||
2021-02-23 | 2020-12-31 | 1.28 | 0.14 | -1.14 | 89 | ||
2020-11-11 | 2020-09-30 | 0.99 | 0.13 | -0.86 | 86 | ||
2020-08-12 | 2020-06-30 | 6.43 | 7.58 | 1.15 | 17 | ||
2020-05-06 | 2020-03-31 | 0.29 | 0.3 | 0.01 | 3 | ||
2020-02-19 | 2019-12-31 | 3.43 | 3.41 | -0.02 | 0 | ||
2019-11-06 | 2019-09-30 | 0.36 | 1.23 | 0.87 | 241 | ||
2019-08-20 | 2019-06-30 | 0.27 | 0.2 | -0.07 | 25 |
Genmab AS Corporate Executives
Elected by the shareholders, the Genmab AS's board of directors comprises two types of representatives: Genmab AS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genmab. The board's role is to monitor Genmab AS's management team and ensure that shareholders' interests are well served. Genmab AS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genmab AS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anthony CPA | Executive CFO | Profile | |
| Anthony Mancini | Executive COO | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 4.634 | Earnings Share 1.77 | Revenue Per Share | Quarterly Revenue Growth 0.353 | Return On Assets |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.